Novartis (NVS) and Ionis (IONS)’ Big Cholesterol Bet Comes Up Short in Late-Stage Trial
Novartis (NVS) and Ionis (IONS) reported that their experimental cholesterol drug, pelacarsen, failed to reduce heart attacks and strokes in a late-stage trial, despite lowering Lp(a) levels. Shares of both companies fell in aftermarket trading. Novartis and Ionis acknowledged the setback but highlighted other pipeline opportunities. The failure removes a potential growth driver for both companies, with Novartis facing greater pressure to replace revenue as older drugs face patent challenges.
How this was made
The 30-second read
Why it matters
The failure removes a potential multibillion‑dollar revenue source for both companies and may shift investor focus to other pipeline candidates.
Market read
Both stocks fell sharply on the news, highlighting the material impact of late‑stage trial outcomes on large‑cap pharma valuations.
What to watch
Novartis' broader pipeline (remibrutinib, other late‑stage assets) may offset the setback.
Background
Pelacarsen was a high‑profile RNA‑based therapy aimed at lowering Lp(a) to reduce cardiovascular events. The trial enrolled >8,000 patients.
Ticker impact
Novartis' Phase III pelacarsen trial failed to reduce cardiovascular events, causing a 5% share drop.
downward pressure, potential further sell-off
First report of a pivotal trial failure for a major pipeline asset; large‑cap move and high market attention.
Ionis' partner drug pelacarsen failed, leading to a 12% share decline.
downward pressure, possible continued weakness
Primary disclosure of a failed late‑stage trial for its lead asset; larger percentage move than Novartis.
Market effects
LPA therapeutics sector faces heightened scrutiny; peers may see valuation pressure.
European biotech markets could see broader risk aversion.
Large‑cap pharma stocks globally may experience short‑term volatility.
Counterpoint
The trial confirms target engagement; future Lp(a) drugs may still succeed with deeper reduction.
Key entities
- companyNovartis AG
Swiss pharma giant, ticker NVS.
- companyIonis Pharmaceuticals, Inc.
RNA‑targeted therapeutics company, ticker IONS.
